Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Breakout Close By
View:
Post by consultant99 on Mar 17, 2022 1:36pm

Breakout Close By

The chart looks very promising with what appears to be a continuation pattern well formed and just waiting for a small uptic to signal a breakout. The MACD graph also appears to be bottoming and also close to signaling a buy. 

The chart suggests the next move higher will take the stock price into the mid to high 0.50s. 

As an investor I am disappointed with the company in not following through on the quarterly newsletters. This is not a good practice. If they want to do things differently so be it, but there is a responsibility to shareholders to be more transparent in my humble opinion. 

That said I believe in the technology.

Further it is encouraging that while waiting the share price is rising for a change.

But that doesn't excuse the lack of transparency when the company is getting potentially very close to qualifying for BTD and commercialization based on the phase 2 trial.

The right results will,send the share price significantly higher and if they have run into another unexpected problem significantly lower.

Its not that some of us haven't been patient waiting.
Would it hurt to explain the delay?
Comment by ScienceFirst on Mar 17, 2022 2:44pm
The company is doing what it needs to do to.  This newsletter is a strategic one, more than any previous one, considering where we're at in terms of patients enrolled, considering that the AUA conference is in May and that there has less patients recruted in December-January.   So if we had to stretch/delay the 3 month cut off date of the newsletter, because we wanted to include ...more  
Comment by ScienceFirst on Mar 17, 2022 3:06pm
The share price is pushing like a woman that wants to deliver. Let's see if this push is for real.  But it smells good.
Comment by StevenBirch on Mar 17, 2022 2:52pm
I don't think it is a delay, it seems they have moved away from the quarterly update and it's better for the short term price. And we don't need a news release just to tell us that there will no longer be a quarterly update.  There is no lack of transparency and if anything the 'delay' could be seen as a positive, that just reporting interim results again is a waste when ...more  
Comment by consultant99 on Mar 18, 2022 1:32am
For what it is worth TD Waterhouse's technical service gave TLT another intermediate buy signal tonight projecting an upside range of 0.56 to 0.58/share. Very encouraging particularly with  the warrants hitting $0.30/share today. I traded most of my shares for warrants more than a year ago buying on average 2 warrants for every share I sold to maximize my leverage. That strategy is ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250